文献速递糖尿病肥胖与代谢综合征

英国国家医疗服务体系2型糖尿病缓解路径项目早期发现:真实世界实施的前瞻性评估

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-08-05

该研究评估了英国国家医疗服务体系(NHS)2型糖尿病缓解路径(T2DR)项目在真实世界中的实施效果。在2022年1月前开始全饮食替代(TDR)的1740人中,960人(55%)完成项目;有两次HbA1c记录的710人中190人(27%)达到缓解,完成者中有两次HbA1c记录的945人中145人(32%)达到缓解。结论认为真实世界实施中2型糖尿病缓解可行,但缓解率低于随机对照试验且数据 ascertainment 更有限。

要点

  • 在2022年1月前开始TDR的1740人中,960人(55%)完成12个月项目。
  • 有两次HbA1c记录的710名参与者中,190人(27%)达到2型糖尿病缓解。
  • 完成项目且有两次HbA1c记录的945人中,145人(32%)达到缓解。

核心结论

  • NHS T2DR项目结果表明,通过规模化服务提供,在科研环境之外实现2型糖尿病缓解是可能的。
  • 然而,与随机对照试验环境相比,真实世界实施中获得的缓解率较低,且数据 ascertainment 更为有限。

研究设计与样本

  • 本研究为全国性前瞻性服务评估,评估T2DR项目实施情况。
  • 纳入对象为英格兰18-65岁、过去6年内诊断为2型糖尿病且在2020年9月1日至2022年12月31日期间被转介至项目的人员。
  • 项目数据与国家糖尿病审计数据链接以获取HbA1c测量值和降糖药物处方。
  • 主要结局为1年时2型糖尿病缓解,定义为两次HbA1c测量值均低于48 mmol/mol、间隔至少3个月、首次HbA1c测量前3个月起未处方降糖药物、且第二次HbA1c测量在项目开始日期后11-15个月记录。
  • 结局评估限于2022年1月前开始12个月项目TDR且无缺失数据的参与者,以及其中在2022年12月31日前完成项目(即第12个月有有效体重记录)且无缺失数据的参与者。

主要发现

  • 2020年9月1日至2022年12月31日期间,7540人被转介至项目;其中1740人在2022年1月前开始TDR,因而至2022年12月底数据提取时有完整12个月机会参与项目。
  • 在2022年1月前开始TDR的1740人中,960人(55%)完成项目(定义为第12个月有体重记录)。
  • 2022年1月前开始项目且无缺失数据的1710名参与者平均体重减轻8.3%(95% CI 7.9-8.6)或9.4 kg(8.9-9.8);完成项目且无缺失数据的945名参与者平均体重减轻9.3%(95% CI 8.8-9.8)或10.3 kg(9.7-10.9)。
  • 在2022年1月前开始项目且有两次HbA1c记录的710名参与者(占1710名的42%)中,190人(27%)达到缓解,平均体重减轻13.4%(95% CI 12.3-14.5)或14.8 kg(13.4-16.3)。
  • 在完成项目的945名参与者中,450人(48%)有两次HbA1c记录;其中145人(32%)达到缓解,平均体重减轻14.4%(95% CI 13.2-15.5)或15.9 kg(14.3-17.4)。

局限性

  • 与随机对照试验环境相比,真实世界实施中获得的缓解率较低,且数据 ascertainment 更为有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomised controlled trials have shown that total diet replacement (TDR) can lead to remission of type 2 diabetes. In 2019, the English National Health Service (NHS) committed to establishing a TDR-based interventional programme delivered at scale within real-world environments; development followed of the NHS Type 2 Diabetes Path to Remission (T2DR) programme, a 12-month behavioural intervention to support weight loss involving an initial 3-month period of TDR. We assessed remission of type 2 diabetes for programme participants. METHODS: In this national prospective service evaluation of programme implementation, people in England aged 18-65 years and diagnosed with type 2 diabetes in the last 6 years were referred to the programme between programme launch on Sept 1, 2020, and Dec 31, 2022. Programme data were linked to the National Diabetes Audit to ascertain HbA1c measurements and glucose-lowering medication prescriptions. The primary outcome was remission of type 2 diabetes at 1 year, defined as two HbA1c measurements of less than 48 mmol/mol recorded at least 3 months apart with no glucose-lowering medications prescribed from 3 months before the first HbA1c measurement, and the second HbA1c measurement recorded 11-15 months after the programme start date. Outcomes were assessed in two ways: for all participants who started TDR on the 12-month programme before January, 2022, for whom there were no missing data; and for all participants who started TDR on the 12-month programme before January, 2022, and had completed the programme (ie, had a valid weight recorded at month 12) by Dec 31, 2022, for whom there were no missing data. FINDINGS: Between Sept 1, 2020, and Dec 31, 2022, 7540 people were referred to the programme; of those, 1740 started TDR before January, 2022, and therefore had a full 12-month opportunity to undertake the programme by the time of data extraction at the end of December, 2022. Of those who started TDR before January, 2022, 960 (55%) completed the programme (defined as having a weight recorded at 12 months). The mean weight loss for the 1710 participants who started the programme before January, 2022 and had no missing data was 8·3% (95% CI 7·9-8·6) or 9·4 kg (8·9-9·8), and the mean weight loss for the 945 participants who completed the programme and had no missing data was 9·3% (8·8-9·8) or 10·3 kg (9·7-10·9). For the subgroup of 710 (42%) of 1710 participants who started the programme before January, 2022, and also had two HbA1c measurements recorded, 190 (27%) had remission, with mean weight loss of 13·4% (12·3-14·5) or 14·8 kg (13·4-16·3). Of the 945 participants who completed the programme, 450 (48%) had two HbA1c measurements recorded; of these, 145 (32%) had remission, with mean weight loss of 14·4% (13·2-15·5) or 15·9 kg (14·3-17·4). INTERPRETATION: Findings from the NHS T2DR programme show that remission of type 2 diabetes is possible outside of research settings, through at-scale service delivery. However, the rate of remission achieved is lower and the ascertainment of data is more limited with implementation in the real world than in randomised controlled trial settings. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Valabhji J, Gorton T, Barron E, et al. Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation. Lancet Diabetes Endocrinol. 2024. PMID: 39116897. doi:10.1016/S2213-8587(24)00194-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。